Researchers at Children's Hospital of Philadelphia (CHOP) highlighted the success of anaplastic lymphoma kinase (ALK) ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK's regulatory filing for ITULATEK® (tree pollen sublingual allergy immunotherapy tablet) for treatment of children and ado ...

Panelists discuss how they will explore optimizing care for patients with ALK-positive non-small cell lung cancer (ALK+ NSCLC) through treatment selection, sequencing strategies, and ...

Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication. Alecensa ...

ARS Pharma enters agreement with ALK-Abelló to co-promote neffy, a needle-free treatment for type I allergic reactions: San Diego Monday, May 5, 2025, 12:00 Hrs [IST] ARS Pharmac ...

Denmark-based allergy immunotherapy specialist ALK Abello (ALKB. DC) today announced that its Itulazax (tree pollen ...

Co-promotion with ARS Pharma based on cost sharing and performance-based revenue sharing.ALK to accelerate build-up of its US paediatric sales channel in a balanced way. Agreement does not change ...

Researchers at Children's Hospital of Philadelphia (CHOP) highlighted the success of anaplastic lymphoma kinase (ALK) inhibition therapy in treating hereditary neuroblastoma, a rare subset of a common ...